Older age at the time of liver biopsy is the important risk factor for advanced fibrosis in patients with chronic hepatitis C

Hepato-Gastroenterology

Volumn 54, Issue 80, 2007, Pages 2324-2327

  Svirtlih, Neda ^a   Jevtovic, Djordje ^a   Simonovic, Jasmina ^a   Delic, Dragan ^a   Dokic, Ljubisa ^a   Gvozdenovic, Eleonora ^a   Boricic, Ivan ^a   Nesic, Zorica ^a   Neskovic, Gorana ^b   Urban, Vladimir ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

Age; Factors; Fibrosis; Hepatitis C virus; Risk

Indexed keywords

VIRUS RNA;

ADOLESCENT; ADULT; AGED; AGING; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PARAMETER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR;

ADOLESCENT; ADULT; AGE FACTORS; AGED; BIOPSY, NEEDLE; DISEASE PROGRESSION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER; LIVER CIRRHOSIS; LOGISTIC MODELS; MALE; MIDDLE AGED; RISK FACTORS;

EID: 37749003297     PISSN: 01726390     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Liang TJ, Rehermann B, Hoofnagle JH: Pathogenesis, natural history, treatment and prevention of hepatitis C. Ann Intern Med 2000; 132:296-305.
2. Seef LB: Natural history of hepatitis C. Hepatology 1997; 26(Suppl 1):21S-28S.
3. Bataller R, North KE, Brener DA: Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003; 7:493-503.
4. Ghany MG, Kleiner DE, Alter H, et al: Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003; 124:97-104.
5. Castera L, Hezode C, Roudot-Thoraval F, et al: Worsening steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and parries liver biopsies. Gut 2003; 52:288-292.
6. Ishak K, Baptista L, Bianchi F, et al: Histological grading and staging of chronic hepatitis. J Hepatology 1995; 22:696-699.
7. NIH consensus statement on Management of Hepatitis C: 2002. NIH Consensus Statements 2002; 19:1-46.
8. Poynard T, Bedossa P, Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997; 349:825-832.
9. Harris HE, Ramsay ME, Andrews N, Eldridge KP: Clinical course of hepatitis C virus during the first decade of infection: cohort study. BMJ 2002; 324:450-453.
10. Matsumura H, Moriyama M, Goto I, et al: Natural course of progression of liver fibrosis in Japanese patients with chronic liver disease type C-a study of 527 patients at one establishment. J Viral Hepat 2000; 7:268-275.
11. Serra MA, Rodriguez F, del Olmo JA, et al: Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage. J Viral Hepat 2003; 10:183-188.
12. Serfaty L, Chazouilleres O, Poujol-Robert A, et al: Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study. Hepatology 1997; 26:776-779.
13. Sagnelli E, Copola N, Scolastico C, et al: HCV genotype and "silent" HBV coinfection: two main risk factors for a more severe liver disease. J Med Virol 2001; 64:350-355.
14. Garcia-Samaniego J, Soriano V, Castila J, et al: Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. Th Hepatitis/HIV Spanish study group. Am J Gastroenterol 1997; 92:1130-1134.
15. Roudot-Thoraval F, Bastle A, Pawlotsky JM, Dhumeaux D: Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6.664 patients. The study group for the prevalence and the epidemiology of hepatitis C virus. Hepatology 1997; 26:485-490.
16. Sherman KE, Rouster SD, Chung RT, Rajicic N-. Hepatitis virus C prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US adults AIDS Clinical Trials Group. Clin Infect Dis 2002; 34:831-837.
17. Cromie SL, Jenkins PJ, Bowden BS, Dudley FJ: Chronic hepatitis C: effects of alcohol on hepatitis activity and viral titre. J Hepatol 1996; 25:821-826.
18. Wiley TE, McCarthy M, Breidi L, Layden TJ: Impact of alcohol on the histological and chnical progression of hepatitis C infection. Hepatology 1998; 28:805-809.
19. Poynard T, Mathurin P, Ching-Lung L, et al: A comparison of fibrosis in chronic liver diseases. J Hepatol 2003; 38:257-265.
20. Kenny-Walsh E: Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish hepatology research group. NEJM 1999; 340:1228-1233.
21. Giannini C, Giannelli F, Monti M, et al: Prevalence of mixed infection by different hepatitis C virus genotypes in patients with hepatitis C virus-related chronic liver disease. J Lab Clin Med 1999; 34:68-73.
22. Kleter B, Brouwer JT, Nevens F, et al: Hepatitis C virus genotypes: epidemiological and clinical associations. Benelux study group on treatment of chronic hepatitis C. Liver 1998; 18:32-38.
23. Fattovich G, Ribero ML, Pantalena M, et al: Eurohep study group on viral hepatitis. Hepatitis C virus genotypes: distribution and clinical significance in patients with cirrhosis type C seen at tertiary referral centres in Europe. J Viral Hepat 2001; 8:206-216.
24. Vince A, Palmovic D, Kutela N, et al: HCV genotypes in patients with chronic hepatitis C in Croatia. Infection 1998; 26:173-177.
25. Stamenkovic G, Zerjav S, Velickovic ZM, et al: Distribution of HCV genotypes among risk groups in Serbia. Eur J Epidemiol 2000; 16:949-954.
26. Hozic D, Stamenkovic G, Bojic I, et al: Role of various virus genotypes in progression of chronic hepatitis C. Vojnosanitet Pregl 2002; 59:141-145.
27. Cathomas G, McGandy CE, Terracciano LM, et al: Detection and typing of hepatitis C RNA in liver biopsies and its relation to histopathology. Virchows Arch 1996; 429:353-358.
28. Bellentani S, Pozzato G, Saccoccio G, et al: Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study. Gut 1999; 44:874-880.
29. Zein NN, Rakela J, Krawitt EL, et al: Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Gut 1996; 125:623-639.
30. Elgouzzi MH, Bouchardaeu F, Pillone J, et al: Hepatitis C virus: routes of infection and genotypes in a cohort of anti-HCV-positive French blood donors. Vox Sang 2000; 79:138-144.
31. Dal Molin G, Ansaldi F, Biagi C, et al: Changing molecular epidemiology of hepatitis C virus infection in Northeast Italy. J Med Virol 2002; 68:352-356.
32. Ramalho F, Costa A, Pires A, et al: Correlation of genotypes and route of transmission with histologic activity and disease stage in chronic hepatitis C. Dig Dis Sci 2000; 45:182-187.
33. Payan C, Roudot-Thoraval F, Marcellin P, et al: Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII study. J Viral Hepat 2005; 12:405-413.
34. Savvas SP, Koskinas J, Sinani C, et al: Changes in epidemiological patterns of HCV infection and their impact on liver disease over the last 20 years in Greece. J Viral Hepat 2005; 12:551-557.
35. Freeman AJ, Law MG, Kaldor JM, Dore GK: Predicting progression to cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003; 10:285-293.
36. Ryder SD, on behalf of Trent Hepatitis C Study Group: Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53:451-455.